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background:  Elafin is a neutrophil elastase inhibitor that protects against myocardial injury in pre-clinical models of ischemic-reperfusion 
injury. We investigated if elafin could inhibit myocardial injury induced during coronary artery bypass graft (CABG) surgery.
methods:  In a randomized double blind placebo controlled clinical trial, 87 patients undergoing CABG surgery were randomized 1:1 to 
Elafin 200 mg or saline placebo. Myocardial injury was measured as cardiac troponin I release over 48 h (area under the curve, AUC) and 
myocardial infarction (MI) identified by magnetic resonance imaging. Inflammation was measured by hs-CRP, and myeloperoxidase (MPO) 
assays.
Results:  Elafin infusion was associated with a >50% reduction in plasma elastase activity, but this did not reduce myocardial injury over 
48 h compared to placebo [ratio of geometric mean troponin 0.74 (95% confidence interval, CI 0.47 to 1.15), P=0.18]. Post hoc analysis 
revealed lower troponin I concentrations at 6 h in elafin treated patients (median 2.4 versus 4.1 μg/L, P=0.035). Elafin had no effect on 
rates of peri-operative MI (elafin 7/34, placebo 5/35 patients) or inflammation with mean differences in hs-CRP of 499 mg/L/48-h (95% CI 
-207 to 1205, P=0.16), and AUC MPO of 238 ng/mL/48-h (95% CI -235 to 711, P=0.32).
conclusion:  We didn’t show a difference with elafin treatment in myocardial injury following ischemia-reperfusion injury. Post-hoc analysis 
revealed a significant reduction in Troponin release at 6 h after skin incision.
 
